Therapeutic difference by TAE between HCC with HCV-Ab and HBV-Ag
Ninomiya, E.; Ohhashi, K.; Murakami, Y.; Yamada, M.; Takano, K.; Nagahama, T.; Ogawa, M.; Horikoshi, N.; Inoue, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(10 Suppl): 1763-1766
1992
ISSN/ISBN: 0385-0684 PMID: 1326926 Document Number: 401225
Transarterial infusion therapy using adriamycin-Lipiodol emulsion (TAE) was used for 30 patients of HCC with HCV-Ab and 20 patients with HBV-Ag. We compared the tumor effect and prognosis in terms of several clinico-pathological factors. The response rate (PR+MR) after TAE was 43% in HCC patients with HCV-Ab and 30% in those with HBV-Ag. One-year survival rate was 89% in HCC patients with HCV-Ab and 58% in HCC patients with HBV-Ag. Thus, there was a significant difference between the two groups. No definite reasons between two groups influencing tumor effect and prognosis is obviously revealed except for portal vein invasion.